Sophie-Charlott Seidenfaden1,2, Julie Linding Kjerulff3, Niels Juul4, Hans Kirkegaard3,5,6, Mette Fogh Møller7, Anna-Marie Bloch Münster8, Morten Thingemann Bøtker3,5,9. 1. Research and Development, Prehospital Emergency Medical Services, Central Denmark Region, Olof Palmes Allé 34 2, Aarhus, Denmark. soseid@rm.dk. 2. Department of Clinical Medicine, Aarhus University, Incuba Skejby, bld. 2, Palle Juul-Jensens Blvd 82, Aarhus, Denmark. soseid@rm.dk. 3. Research and Development, Prehospital Emergency Medical Services, Central Denmark Region, Olof Palmes Allé 34 2, Aarhus, Denmark. 4. Department of Anaesthesiology and Intensive Care, Section North, Neurointensive Care Unit, Aarhus University Hospital, Palle Jull-Jensens Blvd. 161, Aarhus, Denmark. 5. Department of Clinical Medicine, Aarhus University, Incuba Skejby, bld. 2, Palle Juul-Jensens Blvd 82, Aarhus, Denmark. 6. Research Centre for Emergency Medicine, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, Aarhus, Denmark. 7. Department of Clinical Biochemistry, Regional Hospital West Jutland, Gl. Landevej 61, Herning, Denmark. 8. Department of Clinical Biochemistry, Hospital of South West Jutland, Finsensgade 35, Esbjerg, Denmark. 9. Department af Anaesthesiology, Regional Hospital Randers, Skovlyvej 15, Randers, Denmark.
Abstract
BACKGROUND: The biomarker serum S100 calcium-binding protein B (S100B) is used in in-hospital triage of adults with mild traumatic brain injury to rule out intracranial lesions. The biomarker glial fibrillary acidic protein (GFAP) is suggested as a potential diagnostic biomarker for traumatic brain injury. The aim of this study was to investigate the diagnostic accuracy of early prehospital S100B and GFAP measurements to rule out intracranial lesions in adult patients with mild traumatic brain injury. METHODS: Prehospital and in-hospital blood samples were drawn from 566 adult patients with mild traumatic brain injury (Glasgow Coma Scale Score 14-15). The index test was S100B and GFAP concentrations. The reference standard was endpoint adjudication of the traumatic intracranial lesion based on medical records. The primary outcome was prehospital sensitivity of S100B in relation to the traumatic intracranial lesion. RESULTS: Traumatic intracranial lesions were found in 32/566 (5.6%) patients. The sensitivity of S100B > 0.10 μg/L was 100% (95%CI: 89.1;100.0) in prehospital samples and 100% (95% CI 89.1;100.0) in in-hospital samples. The specificity was 15.4% (95%CI: 12.4;18.7) in prehospital samples and 31.5% (27.5;35.6) in in-hospital samples. GFAP was only detected in less than 2% of cases with the assay used. CONCLUSION: Early prehospital and in-hospital S100B levels < 0.10 μg/L safely rules out traumatic intracranial lesions in adult patients with mild traumatic brain injury, but specificity is lower with early prehospital sampling than with in-hospital sampling. The very limited cases with values detectable with our assay do not allow conclusions to be draw regarding the diagnostic accuracy of GFAP. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02867137 .
BACKGROUND: The biomarker serum S100 calcium-binding protein B (S100B) is used in in-hospital triage of adults with mild traumatic brain injury to rule out intracranial lesions. The biomarker glial fibrillary acidic protein (GFAP) is suggested as a potential diagnostic biomarker for traumatic brain injury. The aim of this study was to investigate the diagnostic accuracy of early prehospital S100B and GFAP measurements to rule out intracranial lesions in adult patients with mild traumatic brain injury. METHODS: Prehospital and in-hospital blood samples were drawn from 566 adult patients with mild traumatic brain injury (Glasgow Coma Scale Score 14-15). The index test was S100B and GFAP concentrations. The reference standard was endpoint adjudication of the traumatic intracranial lesion based on medical records. The primary outcome was prehospital sensitivity of S100B in relation to the traumatic intracranial lesion. RESULTS:Traumatic intracranial lesions were found in 32/566 (5.6%) patients. The sensitivity of S100B > 0.10 μg/L was 100% (95%CI: 89.1;100.0) in prehospital samples and 100% (95% CI 89.1;100.0) in in-hospital samples. The specificity was 15.4% (95%CI: 12.4;18.7) in prehospital samples and 31.5% (27.5;35.6) in in-hospital samples. GFAP was only detected in less than 2% of cases with the assay used. CONCLUSION: Early prehospital and in-hospital S100B levels < 0.10 μg/L safely rules out traumatic intracranial lesions in adult patients with mild traumatic brain injury, but specificity is lower with early prehospital sampling than with in-hospital sampling. The very limited cases with values detectable with our assay do not allow conclusions to be draw regarding the diagnostic accuracy of GFAP. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02867137 .
Authors: P E Vos; B Jacobs; T M J C Andriessen; K J B Lamers; G F Borm; T Beems; M Edwards; C F Rosmalen; J L M Vissers Journal: Neurology Date: 2010-11-16 Impact factor: 9.910
Authors: Linda E Pelinka; Alfred Kroepfl; Martin Leixnering; Walter Buchinger; Andreas Raabe; Heinz Redl Journal: J Neurotrauma Date: 2004-11 Impact factor: 5.269
Authors: Kareem R AbdelFattah; Alexander L Eastman; Kim N Aldy; Steven E Wolf; Joseph P Minei; William W Scott; Christopher J Madden; Kim L Rickert; Herb A Phelan Journal: J Trauma Acute Care Surg Date: 2012-09 Impact factor: 3.313
Authors: Andy S Jagoda; Jeffrey J Bazarian; John J Bruns; Stephen V Cantrill; Alisa D Gean; Patricia Kunz Howard; Jamshid Ghajar; Silvana Riggio; David W Wright; Robert L Wears; Aric Bakshy; Paula Burgess; Marlena M Wald; Rhonda R Whitson Journal: Ann Emerg Med Date: 2008-12 Impact factor: 5.721